Skip to main content
Fig. 3 | Orphanet Journal of Rare Diseases

Fig. 3

From: Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding

Fig. 3

ESS higher in patients with detectable HHT-associated genetic variations. All patients met Curacao criteria for HHT. Compared to patients lacking a detectable HHT-associated mutation (n = 11), patients with an ACVRL1 (n = 63) have a significantly higher ESS. Patients with an ENG (n = 40) displayed a trend toward higher ESS. Values represent median ± 5–95% confidence interval, p-values determined by one-way ANOVA with Sidak post-hoc test

Back to article page